The company resolved litigation with CMS, resulting in a one-time $246M non-cash benefit and improved ongoing gross-to-net margins for its Opzelura product.
Filing excerpt
Incyte Corporation (the “Company”) today announced that it has reached an agreement with the Centers for Medicare & Medicaid Services (“CMS”) to resolve the Company’s litigation related to the application of Medicaid rebate rules to Opzelura® (ruxolitinib) cream.
What this signalsFilings often name leadership changes, deals and spending plans.
sec-8kmaterialContractGet every 8-K signal for Incyte and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Incyte this week?”
The Signal API returns 8-K signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-8k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/c26d146b-f42a-4d31-af57-d5e1e164b118 returns this record as JSON. POST /v1/companies/enrich returns every signal for incyte.com.
{
"signal_id": "c26d146b-f42a-4d31-af57-d5e1e164b118",
"signal_type": "sec-8k",
"signal_subtype": "materialContract",
"detected_at": "2026-06-23T07:10:48.281+00:00",
"company": {
"name": "Incyte",
"domain": "incyte.com"
},
"data": {
"detail": "The company resolved litigation with CMS, resulting in a one-time $246M non-cash benefit and improved ongoing gross-to-net margins for its Opzelura product. This significant financial uplift and removal of uncertainty could free up budget for new strategic investments.",
"metrics": {
"timeframe": "current_quarter",
"dollar_context": "One-time, non-cash benefit from reversal of accrual balances related to a litigation settlement.",
"dollar_millions": 246
},
"summary": "Incyte secures $246M benefit and improved margins in CMS settlement for Opzelura",
"excerpts": "Incyte Corporation (the “Company”) today announced that it has reached an agreement with the Centers for Medicare & Medicaid Services (“CMS”) to resolve the Company’s litigation related to the application of Medicaid rebate rules to Opzelura® (ruxolitinib) cream.",
"relevance": 0.9,
"sentiment": "positive",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/879169/000087916926000046/incy-20260622.htm",
"filing_date": "2026-06-22",
"filing_year": 2026,
"fiscal_year_end": "06/22",
"sales_relevance": "Vendor relationship signal",
"signal_category": "strategic"
}
}
curl https://signals.autobound.ai/v1/signals/c26d146b-f42a-4d31-af57-d5e1e164b118 \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"incyte.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.